Market Overview

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of MEDNAX, Inc. Investors

Share:

National securities litigation law firm Glancy
Prongay & Murray LLP
("GPM") announces that a class action
lawsuit has been filed on behalf of investors that purchased MEDNAX,
Inc. ("Mednax" or the "Company") (NYSE: MD)
between February 4, 2016 to July 27, 2017, inclusive (the
"Class Period"). Mednax investors have until September 10,
2018
to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here
to participate.

Investors that suffered losses on their Mednax investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

The Complaint filed on behalf of Mednax investors alleges that
throughout the Class Period, Defendants failed to disclose that the
Company's business model depended on growth from the acquisition of new
practice groups, primarily in anesthesiology; and that Mednax's business
model is not sustainable and its growth was based upon suppressing
physician compensation and enforcing non-compete agreements to deter
physician defections.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Mednax during the Class Period you may move
the Court no later than September 10, 2018 to ask the Court
to appoint you as lead plaintiff. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!